177 related articles for article (PubMed ID: 35707599)
1. Expression of CD44
Sihombing UHM; Andrijono ; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
Gynecol Oncol Rep; 2022 Aug; 42():101005. PubMed ID: 35707599
[TBL] [Abstract][Full Text] [Related]
2. CD44
Sihombing UHM; Andrijono A; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
J Egypt Natl Canc Inst; 2022 Oct; 34(1):44. PubMed ID: 36274112
[TBL] [Abstract][Full Text] [Related]
3. Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.
Feharsal Y; Andrijono A; Singoprawiro CS; Lisnawati L; Pakasi TA; Putra AD; Kusuma F; Anggraeni TD; Erlina E; Sarwanti S; Mardhiyah T
Asian Pac J Cancer Prev; 2024 Feb; 25(2):513-519. PubMed ID: 38415537
[TBL] [Abstract][Full Text] [Related]
4. RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
Somasagara RR; Spencer SM; Tripathi K; Clark DW; Mani C; Madeira da Silva L; Scalici J; Kothayer H; Westwell AD; Rocconi RP; Palle K
Oncogene; 2017 Nov; 36(48):6680-6690. PubMed ID: 28806395
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
[TBL] [Abstract][Full Text] [Related]
6. ZEB1 potentiates chemoresistance in breast cancer stem cells by evading apoptosis.
Shivhare S; Choudhury S; Singh D; Das A
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119528. PubMed ID: 37356459
[TBL] [Abstract][Full Text] [Related]
7. RAD6 promotes chemoresistance in ovarian cancer.
Clark DW; Mani C; Palle K
Mol Cell Oncol; 2018; 5(1):e1392403. PubMed ID: 29404391
[TBL] [Abstract][Full Text] [Related]
8. Markers of tumor-initiating cells predict chemoresistance in breast cancer.
Gong C; Yao H; Liu Q; Chen J; Shi J; Su F; Song E
PLoS One; 2010 Dec; 5(12):e15630. PubMed ID: 21187973
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
10. p63 inhibits CD44
Guo JJ; Xu HS; Wu G; Ma ZY
Exp Ther Med; 2017 Nov; 14(5):4693-4696. PubMed ID: 29201169
[TBL] [Abstract][Full Text] [Related]
11. Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer.
Somasagara RR; Tripathi K; Spencer SM; Clark DW; Barnett R; Bachaboina L; Scalici J; Rocconi RP; Piazza GA; Palle K
Biochem Biophys Res Commun; 2016 Jan; 469(3):449-55. PubMed ID: 26679603
[TBL] [Abstract][Full Text] [Related]
12. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
14. [Pilot study on the correlation between high incidence of CD44+/CD24 -/low/ABCG2- cells and poor prognosis in breast cancer].
Gong JF; Yuan YH; Song GH; Yu J; Han Y; Jia J; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 40(5):465-70. PubMed ID: 18931706
[TBL] [Abstract][Full Text] [Related]
15. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival.
Meng E; Long B; Sullivan P; McClellan S; Finan MA; Reed E; Shevde L; Rocconi RP
Clin Exp Metastasis; 2012 Dec; 29(8):939-48. PubMed ID: 22610780
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
17. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Lee HE; Kim JH; Kim YJ; Choi SY; Kim SW; Kang E; Chung IY; Kim IA; Kim EJ; Choi Y; Ryu HS; Park SY
Br J Cancer; 2011 May; 104(11):1730-8. PubMed ID: 21559013
[TBL] [Abstract][Full Text] [Related]
18. Identification of An mtDNA Setpoint Associated with Highest Levels of CD44 Positivity and Chemoresistance in HGC-27 and MKN-45 Gastric Cancer Cell Lines.
Terzioğlu G; Türksoy Ö; Bayrak ÖF
Cell J; 2018 Oct; 20(3):312-317. PubMed ID: 29845783
[TBL] [Abstract][Full Text] [Related]
19. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
20. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
